Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Epigenomics GMBH

This article was originally published in Start Up

Executive Summary

Epigenomics is developing diagnostics based on individuals' genetic profiles. Its core technology is based on measurements of DNA methylation: the company believes methyl groups, which stick up like flags from stretches of DNA, may indicate the absence or presence of disease.

You may also be interested in...



Epigenomics Gets What Companies Rarely Do: A Huge Deal

Roche Diagnostics and Epigenomics AG, a start-up diagnostics company, have signed a three-year collaboration to find new cancer diagnostic markers, a deal that could bring Epigenomics as much as $100 million--if all of the markers covered get to market. Epigenomics is working on DNA methylation based biomarkers for cancer and will identify the markers; Roche will develop them into tests and market them worldwide.

Epigenomics Gets What Companies Rarely Do: A Huge Deal

Roche Diagnostics and Epigenomics AG, a start-up diagnostics company, have signed a three-year collaboration to find new cancer diagnostic markers, a deal that could bring Epigenomics as much as $100 million--if all of the markers covered get to market. Epigenomics is working on DNA methylation based biomarkers for cancer and will identify the markers; Roche will develop them into tests and market them worldwide.

Overcoming Skepticism About Cancer Diagnostics

In cancer diagnostics skepticism and optimism exist side by side. This is evident from a growing dichotomy between the spurt of early research projects, fueled by new technologies and increased government spending, and the lack of investor interest. Despite a brutal financing market and past disappointments, a few start-ups determined to address the field's unmet needs are pursuing development of new markers and detection technologies and gaining momentum.

Topics

Related Companies

UsernamePublicRestriction

Register

MT037091

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel